We also attempted to examine the association between HE4 expression and clinicopathological features such as grade, stage, metastasis presence, hormone receptor (HR) status, HER2 expression, and P53 mutation status to assess the eligibility of this factor as an early detection tool or a prognostic biomarker in BC. Here, WFDC2 is linked to breast cancer.